Carbamazepine Labeling To Advise Genetic Screen To Avoid Side Effect
Labeling for carbamazepine drugs will be revised to recommend patients of Asian descent be genetically screened prior to starting therapy to help identify those at an increased risk of a serious side effect, FDA announced Dec. 12
You may also be interested in...
FDA took warfarin one step into the world of personalized medicine Aug. 16 with labeling changes that inform patients and doctors about the usefulness of genetic testing before beginning therapy with the blood thinner
HIV community is pushing back against the change, arguing that revenue lost from reduced reimbursement will cripple providers, which use the extra funds for wrap-around patient support and services.
As MACPAC moves toward formal recommendations, a CBO analysis finds that differential Medicaid rebates for drugs approved through the accelerated pathway could save the federal government up to $1bn over five years.